Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2004 1
2006 3
2007 1
2009 1
2014 1
2015 1
2017 2
2018 1
2019 3
2020 4
2021 1
Text availability
Article attribute
Article type
Publication date

Search Results

19 results
Results by year
Filters applied: . Clear all
Page 1
Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial.
Pfisterer J, Shannon CM, Baumann K, Rau J, Harter P, Joly F, Sehouli J, Canzler U, Schmalfeldt B, Dean AP, Hein A, Zeimet AG, Hanker LC, Petit T, Marmé F, El-Balat A, Glasspool R, de Gregorio N, Mahner S, Meniawy TM, Park-Simon TW, Mouret-Reynier MA, Costan C, Meier W, Reinthaller A, Goh JC, L'Haridon T, Baron Hay S, Kommoss S, du Bois A, Kurtz JE; AGO-OVAR 2.21/ENGOT-ov 18 Investigators. Pfisterer J, et al. Among authors: baron hay s. Lancet Oncol. 2020 May;21(5):699-709. doi: 10.1016/S1470-2045(20)30142-X. Epub 2020 Apr 16. Lancet Oncol. 2020. PMID: 32305099 Clinical Trial.
Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer.
Coleman RL, Fleming GF, Brady MF, Swisher EM, Steffensen KD, Friedlander M, Okamoto A, Moore KN, Efrat Ben-Baruch N, Werner TL, Cloven NG, Oaknin A, DiSilvestro PA, Morgan MA, Nam JH, Leath CA 3rd, Nicum S, Hagemann AR, Littell RD, Cella D, Baron-Hay S, Garcia-Donas J, Mizuno M, Bell-McGuinn K, Sullivan DM, Bach BA, Bhattacharya S, Ratajczak CK, Ansell PJ, Dinh MH, Aghajanian C, Bookman MA. Coleman RL, et al. Among authors: baron hay s. N Engl J Med. 2019 Dec 19;381(25):2403-2415. doi: 10.1056/NEJMoa1909707. Epub 2019 Sep 28. N Engl J Med. 2019. PMID: 31562800 Free PMC article. Clinical Trial.
Electrophysiological and phenotypic profiles of taxane-induced neuropathy.
Timmins HC, Li T, Huynh W, Kiernan MC, Baron-Hay S, Boyle F, Goldstein D, Park SB. Timmins HC, et al. Among authors: baron hay s. Clin Neurophysiol. 2020 Aug;131(8):1979-1985. doi: 10.1016/j.clinph.2020.02.028. Epub 2020 Apr 2. Clin Neurophysiol. 2020. PMID: 32291143
Frontline treatment of epithelial ovarian cancer.
Goh J, Mohan GR, Ladwa R, Ananda S, Cohen PA, Baron-Hay S. Goh J, et al. Among authors: baron hay s. Asia Pac J Clin Oncol. 2015 Dec;11 Suppl 6:1-16. doi: 10.1111/ajco.12449. Asia Pac J Clin Oncol. 2015. PMID: 26669253 Review.
Optimal clinical assessment strategies for chemotherapy-induced peripheral neuropathy (CIPN): a systematic review and Delphi survey.
McCrary JM, Goldstein D, Boyle F, Cox K, Grimison P, Kiernan MC, Krishnan AV, Lewis CR, Webber K, Baron-Hay S, Horvath L, Park SB; IN FOCUS Delphi working party. McCrary JM, et al. Among authors: baron hay s. Support Care Cancer. 2017 Nov;25(11):3485-3493. doi: 10.1007/s00520-017-3772-y. Epub 2017 Jun 7. Support Care Cancer. 2017. PMID: 28589310 Review.
Why pathologists and oncologists should know about tumour-infiltrating lymphocytes (TILs) in triple-negative breast cancer: an Australian experience of 139 cases.
Fuchs TL, Pearson A, Pickett J, Diakos C, Dewar R, Chan D, Guminski A, Menzies A, Baron-Hay S, Sheen A, Sioson L, Chou A, Gill AJ. Fuchs TL, et al. Among authors: baron hay s. Pathology. 2020 Aug;52(5):515-521. doi: 10.1016/j.pathol.2020.04.004. Epub 2020 Jun 14. Pathology. 2020. PMID: 32553444
Tailored NEOadjuvant epirubicin, cyclophosphamide and Nanoparticle Albumin-Bound paclitaxel for breast cancer: The phase II NEONAB trial-Clinical outcomes and molecular determinants of response.
Murphy C, Muscat A, Ashley D, Mukaro V, West L, Liao Y, Chisanga D, Shi W, Collins I, Baron-Hay S, Patil S, Lindeman G, Khasraw M. Murphy C, et al. Among authors: baron hay s. PLoS One. 2019 Feb 14;14(2):e0210891. doi: 10.1371/journal.pone.0210891. eCollection 2019. PLoS One. 2019. PMID: 30763338 Free PMC article. Clinical Trial.
19 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page